19.39 -0.11 (-0.56%)

46.44% Fall from 52W High

8,822 XNAS Volume

XNAS 19 Mar, 2025 10:22 AM (EDT)



Insider Trading disclosures for ArriVent BioPharma Inc.

The latest disclosure was made by Robin LaChapelle in ArriVent BioPharma Inc. where a trade of 120,000 Stock Option (right to buy) done was reported to US exchanges on Feb. 3, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Robin LaChapelle Chief Operating Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 120,000 120,000 - - Stock Option (right to buy)
Stuart Lutzker Director, President of R&D Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 120,000 120,000 - - Stock Option (right to buy)
James Paul Kastenmayer General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 102,000 102,000 - - Stock Option (right to buy)
Winston Kung Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 120,000 120,000 - - Stock Option (right to buy)
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.24 per share. 19 Sep 2024 2,700 99,717 - 6.2 16,848 Common Stock
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.28 per share. 19 Sep 2024 2,867 102,584 - 2.3 6,537 Common Stock
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.28 per share. 19 Sep 2024 7,164 109,748 - 2.3 16,334 Common Stock
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.28 per share. 19 Sep 2024 2,471 112,219 - 2.3 5,634 Common Stock
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.65 per share. 19 Sep 2024 12,364 124,583 - 3.7 45,129 Common Stock
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Sep 2024 2,471 2,460 - - Stock Option (right to buy)
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Sep 2024 2,867 22,637 - - Stock Option (right to buy)
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Sep 2024 2,700 56,471 - - Stock Option (right to buy)
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Sep 2024 12,364 18,865 - - Stock Option (right to buy)
Robin LaChapelle Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Sep 2024 7,164 15,473 - - Stock Option (right to buy)
John A. Hohneker Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 May 2024 29,550 29,550 - - Stock Option (right to buy)
Kristine Peterson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Apr 2024 28,587 28,587 - - Stock Option (right to buy)
Carl L. Gordon Director, Ten Percent Owner 30 Jan 2024 469,615 1,291,442 - - Common Stock
James I. Healy Director 30 Jan 2024 1,252,308 0 - - Series B Preferred Stock
James I. Healy Director 30 Jan 2024 1,252,308 1,252,308 - - Common Stock
James I. Healy Director Purchase of securities on an exchange or from another person at price $ 18.00 per share. 30 Jan 2024 444,444 1,696,752 - 18 7,999,992 Common Stock
Carl L. Gordon Director, Ten Percent Owner 30 Jan 2024 821,827 0 - - Series A Preferred Stock
Carl L. Gordon Director, Ten Percent Owner 30 Jan 2024 821,827 0 - - Series A Preferred Stock
Carl L. Gordon Director, Ten Percent Owner 30 Jan 2024 469,615 0 - - Series B Preferred Stock
Carl L. Gordon Director, Ten Percent Owner 30 Jan 2024 469,615 0 - - Series B Preferred Stock
Carl L. Gordon Director, Ten Percent Owner 30 Jan 2024 469,615 1,291,442 - - Common Stock
Carl L. Gordon Director, Ten Percent Owner 30 Jan 2024 821,827 821,827 - - Common Stock
Carl L. Gordon Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 18.00 per share. 30 Jan 2024 222,222 1,513,664 - 18 3,999,996 Common Stock
Carl L. Gordon Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 18.00 per share. 30 Jan 2024 222,222 1,513,664 - 18 3,999,996 Common Stock
Carl L. Gordon Director, Ten Percent Owner 30 Jan 2024 821,827 821,827 - - Common Stock
Christian W. Nolet Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jan 2024 17,884 17,884 - - Stock Option (right to buy)
Bahija Jallal Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jan 2024 17,884 17,884 - - Stock Option (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures